Free Trial
→ Uranium Mine Flood That Sparked a 2006 Price Surge Returns (From Digest Publishing) (Ad)tc pixel Free SRTA Stock Alerts

Strata Critical Medical (SRTA) Financials

$5.64 -0.13 (-2.17%)
As of 12:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Strata Critical Medical

Annual Income Statements for Strata Critical Medical

This table shows Strata Critical Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2019 9/30/2020 9/30/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 21 13 -40 -27 -56 -27 41
Consolidated Net Income / (Loss)		 -11 -10 -40 -27 -56 -27 41
Net Income / (Loss) Continuing Operations		 21 13 -40 -27 -56 -16 -20
Total Pre-Tax Income 		-11 -10 -44 -28 -58 -16 -20
Total Operating Income		 -12 -10 -24 -54 -68 -23 -22
Total Gross Profit		 31 23 11 22 42 30 41
Total Revenue		 31 23 51 146 225 147 197
Operating Revenue		 31 23 51 146 225 147 197
Total Cost of Revenue		 0.00 0.00 40 124 183 117 156
Operating Cost of Revenue		 - - 40 124 183 117 156
Total Operating Expenses		 11 10 35 76 110 52 63
Selling, General & Admin Expense		 10 9.29 30 63 95 51 61
Amortization Expense		 - - - - - 1.26 2.60
Total Other Income / (Expense), net		 0.70 0.20 -20 25 11 6.36 2.29
Interest & Investment Income		 - - 0.00 -2.16 8.45 7.21 -0.95
Other Income / (Expense), net		 0.00 0.00 -20 24 2.13 -0.85 3.24
Income Tax Expense		 0.00 0.00 -3.64 -0.77 -1.47 0.00 0.00
Net Income / (Loss) Discontinued Operations		 - - - - - -11 61
Basic Earnings per Share		 - - ($0.93) ($0.38) ($0.76) ($0.35) $0.50
Weighted Average Basic Shares Outstanding		 25.14M 25.21M 42.88M 71.24M 73.52M 77.50M 82.09M
Diluted Earnings per Share		 - - ($0.93) ($0.38) ($0.76) ($0.35) $0.50
Weighted Average Diluted Shares Outstanding		 25.14M 25.21M 42.88M 71.24M 73.52M 77.50M 82.09M
Weighted Average Basic & Diluted Shares Outstanding		 25.14M 25.21M 42.88M 72.04M 75.43M 79.69M 86.99M

Quarterly Income Statements for Strata Critical Medical

This table shows Strata Critical Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.23 -11 -1.95 -9.79 -3.49 -3.74 57 -8.83 2.15 -11 -7.62
Consolidated Net Income / (Loss)		 -4.23 -11 -1.95 -9.79 -3.49 -3.74 57 -8.83 2.15 -11 -7.62
Net Income / (Loss) Continuing Operations		 -4.23 -11 -5.63 -9.79 -1.61 -3.41 -9.66 -3.17 2.40 -11 -7.62
Total Pre-Tax Income 		-4.32 -11 -5.63 -9.90 -1.61 -3.41 -9.66 -3.18 2.40 -11 -7.62
Total Operating Income		 -9.87 -12 -7.09 -8.37 -5.69 -4.64 -5.62 -4.19 -2.97 -5.41 -3.83
Total Gross Profit		 10 16 7.51 13 7.05 9.01 11 -0.20 14 15 17
Total Revenue		 52 68 36 54 36 45 49 23 67 73 74
Operating Revenue		 52 68 36 54 36 45 49 23 67 73 74
Total Cost of Revenue		 41 52 29 42 29 36 39 23 53 57 57
Operating Cost of Revenue		 41 52 29 42 29 36 39 23 53 57 57
Total Operating Expenses		 20 29 15 21 13 14 16 3.99 17 21 21
Selling, General & Admin Expense		 17 25 14 19 12 13 16 7.12 16 14 15
Amortization Expense		 - - - - 0.41 0.36 0.36 - 1.49 6.63 5.51
Total Other Income / (Expense), net		 5.55 0.88 1.47 -1.53 4.07 1.23 -4.04 1.02 5.38 -5.11 -3.78
Interest & Investment Income		 2.07 1.79 1.76 3.66 1.32 1.16 -4.07 0.64 0.47 0.33 -1.14
Other Income / (Expense), net		 3.48 -0.91 -0.30 -3.12 2.75 0.08 0.03 0.38 4.90 -5.44 -2.65
Income Tax Expense		 -0.08 0.05 0.00 -0.11 0.00 0.00 0.00 -0.00 0.00 0.00 0.00
Net Income / (Loss) Discontinued Operations		 - - 3.67 - -1.88 -0.33 67 - -0.25 0.00 0.00
Basic Earnings per Share		 ($0.06) ($0.15) ($0.03) ($0.11) ($0.04) ($0.05) $0.70 ($0.11) $0.03 ($0.12) ($0.09)
Weighted Average Basic Shares Outstanding		 75.80M 77.60M 78.04M 77.50M 79.89M 81.30M 82.45M 82.09M 85.32M 86.21M 88.27M
Diluted Earnings per Share		 ($0.06) ($0.15) ($0.03) ($0.11) ($0.04) ($0.05) $0.70 ($0.11) $0.03 ($0.12) ($0.09)
Weighted Average Diluted Shares Outstanding		 75.80M 77.60M 78.04M 77.50M 79.89M 81.30M 82.45M 82.09M 90.17M 86.21M 88.27M
Weighted Average Basic & Diluted Shares Outstanding		 77.35M 77.93M 78.31M 79.69M 81.02M 81.70M 86.37M 86.99M 86.53M 88.47M 89.32M

Annual Cash Flow Statements for Strata Critical Medical

This table details how cash moves in and out of Strata Critical Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2019 9/30/2020 9/30/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -11 -10 -4.69 41 -15 -9.37 12
Net Cash From Operating Activities		 -10 -11 -16 -37 -32 -2.52 -49
Net Cash From Continuing Operating Activities		 -10 -11 -16 -37 -32 -2.52 -49
Net Income / (Loss) Continuing Operations		 -11 -10 -40 -27 -56 -27 41
Consolidated Net Income / (Loss)		 -11 -10 -40 -27 -56 -27 41
Depreciation Expense		 0.47 0.53 0.60 5.73 7.11 5.96 8.19
Amortization Expense		 - - 0.00 -1.09 -6.52 -3.99 -2.21
Non-Cash Adjustments To Reconcile Net Income		 0.32 0.50 30 -14 31 26 -89
Changes in Operating Assets and Liabilities, net		 -0.25 -1.69 -5.84 -0.79 -8.20 -2.94 -7.14
Net Cash From Investing Activities		 -1.05 -0.38 -321 79 17 -1.02 70
Net Cash From Continuing Investing Activities		 -1.05 -0.38 -321 79 17 -1.02 70
Purchase of Property, Plant & Equipment		 -0.60 -0.38 -0.80 -0.73 -2.11 -31 -9.60
Acquisitions		 -0.45 0.00 -23 -48 -0.04 -4.35 -68
Purchase of Investments		 0.00 0.00 -309 -228 -266 -143 -146
Sale and/or Maturity of Investments		 0.00 0.00 11 356 285 177 296
Other Investing Activities, net		 - - - - - 0.00 -2.81
Net Cash From Financing Activities		 0.12 1.18 332 -1.08 -0.08 -5.76 -8.91
Net Cash From Continuing Financing Activities		 0.12 1.18 332 -1.08 -0.08 -5.76 -8.91
Repurchase of Common Equity		 - - - - 0.00 -0.24 0.00
Other Financing Activities, net		 0.12 0.02 214 -1.08 -0.08 -5.52 -8.91
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.02 0.00 0.09

Quarterly Cash Flow Statements for Strata Critical Medical

This table details how cash moves in and out of Strata Critical Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 9.04 -9.69 -6.96 -1.76 16 25 -37 8.22 28 -42 19
Net Cash From Operating Activities		 -16 8.43 6.36 -1.75 -0.25 -3.06 -37 -8.31 3.89 5.69 9.46
Net Cash From Continuing Operating Activities		 -16 8.39 6.36 -1.75 -0.25 -3.06 -37 -8.31 3.89 5.69 9.46
Net Income / (Loss) Continuing Operations		 -4.23 -11 -1.95 -9.79 -3.49 -3.74 57 -8.83 2.15 -11 -7.62
Consolidated Net Income / (Loss)		 -4.23 -11 -1.95 -9.79 -3.49 -3.74 57 -8.83 2.15 -11 -7.62
Depreciation Expense		 1.59 1.56 1.28 1.53 1.70 1.78 1.70 3.01 3.06 8.52 7.31
Amortization Expense		 -1.48 -0.82 -0.82 -0.87 -0.72 -0.79 -0.22 -0.48 -0.27 -0.18 -0.06
Non-Cash Adjustments To Reconcile Net Income		 0.87 12 5.55 7.27 1.47 5.57 -105 8.87 3.92 3.97 6.67
Changes in Operating Assets and Liabilities, net		 -12 6.65 2.30 0.11 0.81 -5.88 8.83 -11 -4.98 3.90 3.15
Net Cash From Investing Activities		 25 -17 -13 3.98 20 29 2.40 18 25 -44 13
Net Cash From Continuing Investing Activities		 25 -17 -13 3.98 20 28 2.63 18 25 -44 13
Purchase of Property, Plant & Equipment		 -0.82 -16 -9.31 -4.58 -2.61 -2.53 -2.60 -1.85 -5.18 -2.49 -0.40
Acquisitions		 -0.31 -0.75 -2.83 -0.46 -0.53 -0.43 -65 -1.52 -0.30 -35 -1.41
Sale and/or Maturity of Investments		 103 - 65 9.50 108 44 122 23 31 - 15
Net Cash From Financing Activities		 0.05 -1.21 -0.73 -3.87 -4.25 -1.14 -1.79 -1.74 -0.86 -4.21 -4.10
Net Cash From Continuing Financing Activities		 0.05 -1.21 -0.73 -3.87 -4.25 -1.14 -1.79 -1.74 -0.86 -4.21 -4.10
Repayment of Debt		 - - - - 0.00 - - - -0.33 -0.01 -0.02
Other Financing Activities, net		 0.05 -0.96 -0.73 -3.87 -4.25 -1.14 -1.79 -1.74 -0.53 -4.20 -4.08
Cash Income Taxes Paid		 - - - - - - - 0.06 - - 0.49

Annual Balance Sheets for Strata Critical Medical

This table presents Strata Critical Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 278 278 336 325 295 257 325
Total Current Assets		 1.43 0.90 295 218 206 161 126
Cash & Equivalents		 1.31 0.85 2.60 41 28 16 31
Restricted Cash		 - - 0.63 3.09 1.15 0.26 0.26
Short-Term Investments		 - - 279 151 138 109 30
Accounts Receivable		 - - 5.55 11 21 20 40
Prepaid Expenses		 0.13 0.05 6.80 12 18 4.68 25
Plant, Property, & Equipment, net		 0.00 0.00 2.05 2.04 2.90 28 36
Total Noncurrent Assets		 276 277 39 105 86 67 163
Goodwill		 - - 13 39 40 16 88
Intangible Assets		 - - 24 46 21 7.96 48
Other Noncurrent Operating Assets		 - 0.00 0.95 19 25 2.95 27
Total Liabilities & Shareholders' Equity		 278 278 336 325 295 257 325
Total Liabilities		 26 47 45 51 61 35 46
Total Current Liabilities		 0.37 0.39 13 27 35 23 20
Accounts Payable		 0.14 0.16 6.37 17 24 9.22 19
Other Current Liabilities		 - - 0.44 3.36 4.79 0.68 0.65
Total Noncurrent Liabilities		 26 46 32 24 25 12 27
Noncurrent Deferred & Payable Income Tax Liabilities		 - - 0.14 1.88 0.45 0.00 0.35
Other Noncurrent Operating Liabilities		 26 46 32 22 25 8.14 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.00 5.00 291 274 234 222 279
Total Preferred & Common Equity		 5.00 5.00 291 274 234 222 279
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 5.00 5.00 291 274 234 222 279
Common Stock		 2.67 23 369 376 390 407 425
Retained Earnings		 2.33 -18 -76 -104 -160 -187 -146
Accumulated Other Comprehensive Income / (Loss)		 - - -0.90 2.29 3.96 1.75 0.00

Quarterly Balance Sheets for Strata Critical Medical

This table presents Strata Critical Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 318 283 280 283 251 258 335 328 333 329
Total Current Assets		 209 194 183 172 152 156 122 124 121 125
Cash & Equivalents		 37 37 26 20 35 59 23 59 16 35
Restricted Cash		 1.46 1.30 2.06 1.38 0.86 1.56 0.26 0.26 0.26 0.27
Short-Term Investments		 136 114 116 116 85 55 53 0.07 6.44 6.51
Accounts Receivable		 21 24 28 24 22 28 38 40 43 43
Prepaid Expenses		 13 18 11 9.56 9.32 13 8.76 25 55 40
Plant, Property, & Equipment, net		 3.32 3.47 22 31 33 34 39 40 41 40
Total Noncurrent Assets		 105 85 75 81 66 68 174 163 171 164
Goodwill		 39 40 40 43 42 44 85 89 107 102
Intangible Assets		 42 20 14 14 14 14 50 46 60 59
Other Noncurrent Operating Assets		 24 26 22 24 10 9.91 40 28 4.03 3.38
Total Liabilities & Shareholders' Equity		 318 283 280 283 251 258 335 328 333 329
Total Liabilities		 55 46 51 49 31 35 52 42 53 53
Total Current Liabilities		 30 23 30 27 22 26 28 21 46 45
Accounts Payable		 19 11 17 16 11 14 27 20 18 14
Other Current Liabilities		 4.76 4.43 4.15 4.47 3.36 3.52 0.65 0.99 27 31
Total Noncurrent Liabilities		 24 23 21 22 8.94 8.51 24 21 7.60 7.39
Noncurrent Deferred & Payable Income Tax Liabilities		 1.43 0.36 0.40 0.30 0.18 0.21 0.18 0.27 0.27 0.27
Other Noncurrent Operating Liabilities		 23 23 20 22 8.76 8.30 24 21 7.33 7.12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 263 237 229 233 220 223 283 286 279 276
Total Preferred & Common Equity		 263 237 229 233 220 223 283 286 279 276
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 263 237 229 233 220 223 283 286 279 276
Common Stock		 387 397 402 406 407 411 420 429 433 438
Retained Earnings		 -126 -164 -175 -177 -190 -194 -137 -143 -154 -162
Accumulated Other Comprehensive Income / (Loss)		 1.73 3.11 2.78 4.17 3.07 5.97 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Strata Critical Medical

This table displays calculated financial ratios and metrics derived from Strata Critical Medical's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2019 9/30/2020 9/30/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 34,375,000.00 69,427,682.00 71,653,281.00 74,633,754.00 - 86,366,526.00
DEI Adjusted Shares Outstanding		 0.00 34,375,000.00 69,427,682.00 71,653,281.00 74,633,754.00 - 86,366,526.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.39 -0.58 -0.38 -0.75 - 0.48
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -24.88% 115.61% 189.20% 54.11% 10.44% 34.28%
EBITDA Growth		 0.00% 11.17% -342.99% 43.36% -165.07% 49.84% 38.60%
EBIT Growth		 0.00% 10.24% -326.25% 33.63% -125.20% 47.30% 18.24%
NOPAT Growth		 0.00% 10.24% -132.58% -122.18% -27.25% 50.19% 0.76%
Net Income Growth		 0.00% 6.26% -294.21% 31.94% -105.71% 51.30% 251.42%
EPS Growth		 0.00% 0.00% 0.00% 59.14% -100.00% 53.95% 242.86%
Operating Cash Flow Growth		 0.00% -5.01% -44.34% -137.78% 12.88% 92.21% -1,841.80%
Free Cash Flow Firm Growth		 0.00% 0.00% -634.86% -49.96% 67.32% -42.11% -1,597.74%
Invested Capital Growth		 0.00% -79.82% 118.34% 825.41% -15.52% 39.57% 254.53%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 4.33% 2.84% -26.32%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -46.75% 44.69% 31.29%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -42.36% 42.63% 17.73%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -30.59% 44.55% 2.71%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -49.34% 46.93% 2.38%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -52.00% 49.28% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 5.46% -32.48% -0.67% 75.03% -15.47%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 1.08% -35.19%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -23.67% -2.35% 5.20%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 20.82% 15.24% 18.71% 23.69% 20.86%
EBITDA Margin		 -35.48% -41.96% -86.21% -16.89% -29.04% -13.19% -6.67%
Operating Margin		 -37.00% -44.21% -47.68% -36.63% -30.25% -13.64% -11.34%
EBIT Margin		 -37.00% -44.21% -87.39% -20.05% -29.31% -13.98% -9.69%
Profit (Net Income) Margin		 -34.74% -43.36% -79.27% -18.66% -24.90% -10.98% 20.97%
Tax Burden Percent		 100.00% 100.00% 91.66% 97.25% 97.45% 99.07% -206.06%
Interest Burden Percent		 93.91% 98.08% 98.96% 95.66% 87.20% 79.26% 104.99%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -85.26% -65.17% -29.58% -11.22%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -89.53% -60.53% -27.18% -62.55%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 75.62% 43.12% 17.61% 27.72%
Return on Equity (ROE)		 -4.31% -4.21% -15.33% -9.63% -22.04% -11.97% 16.51%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -841.92% -246.25% -48.34% -62.62% -123.22%
Operating Return on Assets (OROA)		 -4.16% -3.73% -14.39% -8.87% -21.29% -12.61% -6.57%
Return on Assets (ROA)		 -3.90% -3.66% -13.05% -8.25% -18.09% -9.90% 14.21%
Return on Common Equity (ROCE)		 -0.09% -0.09% -8.70% -9.63% -22.04% -11.97% 16.51%
Return on Equity Simple (ROE_SIMPLE)		 -216.76% -203.20% -13.75% -9.93% -23.93% -12.30% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.08 -7.25 -17 -37 -48 -24 -16
NOPAT Margin		 -25.90% -30.94% -33.38% -25.64% -21.18% -9.55% -7.94%
Net Nonoperating Expense Percent (NNEP)		 -0.99% -1.05% -8.27% 4.27% -4.63% -2.41% 51.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -20.35% -10.70% -5.61%
Cost of Revenue to Revenue		 0.00% 0.00% 79.18% 84.76% 81.29% 76.31% 79.14%
SG&A Expenses to Revenue		 33.58% 39.65% 59.66% 42.78% 42.27% 32.86% 30.88%
R&D to Revenue		 2.41% 3.67% 3.33% 3.79% 2.05% 1.28% 0.00%
Operating Expenses to Revenue		 35.99% 43.33% 68.50% 51.88% 48.96% 37.33% 32.20%
Earnings before Interest and Taxes (EBIT)		 -12 -10 -44 -29 -66 -35 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -9.83 -44 -25 -65 -33 -13
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 50.05 71.44 2.48 0.93 1.12 1.50 1.49
Price to Tangible Book Value (P/TBV)		 50.05 71.44 2.85 1.36 1.52 1.99 2.90
Price to Revenue (P/Rev)		 8.02 15.24 14.29 1.76 1.17 1.34 2.11
Price to Earnings (P/E)		 12.11 26.50 0.00 0.00 0.00 0.00 10.05
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 8.26% 3.77% 0.00% 0.00% 0.00% 0.00% 9.95%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 51.24 0.77 1.44 2.19 1.63
Enterprise Value to Revenue (EV/Rev)		 7.03 13.04 8.69 0.42 0.43 0.82 1.80
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 22.64 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.10 -1.15 -1.07 -0.84 -0.71 -0.65 -0.44
Leverage Ratio		 1.10 1.15 1.17 1.17 1.22 1.21 1.16
Compound Leverage Factor		 1.04 1.13 1.16 1.12 1.06 0.96 1.22
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 98.01% 97.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 1.99% 2.16% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.74 4.45 10.14 3.46 2.57 5.90 5.55
Noncontrolling Interest Sharing Ratio		 98.01% 97.93% 43.27% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 3.85 2.29 23.07 8.20 5.81 7.07 6.38
Quick Ratio		 3.52 2.17 22.49 7.63 5.27 6.54 5.11
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 13 -72 -108 -35 -50 -172
Operating Cash Flow to CapEx		 -1,705.63% -2,869.50% -1,949.44% -5,086.30% -1,641.25% -8.16% -509.79%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.11 0.08 0.16 0.44 0.73 0.90 0.68
Accounts Receivable Turnover		 0.00 0.00 0.00 17.79 14.13 11.68 6.60
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 71.59 91.24 14.71 6.07
Accounts Payable Turnover		 0.00 0.00 12.26 10.81 9.06 10.36 11.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 20.51 25.84 31.26 55.34
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 29.78 33.75 40.27 35.22 33.18
Cash Conversion Cycle (CCC)		 0.00 0.00 -29.78 -13.24 -14.43 -3.96 22.16
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -26 -47 8.57 79 67 94 218
Invested Capital Turnover		 -1.20 -0.64 -2.65 3.32 3.08 3.10 1.41
Increase / (Decrease) in Invested Capital		 0.00 -21 55 71 -12 27 156
Enterprise Value (EV)		 219 305 439 61 96 204 354
Market Capitalization		 250 357 722 257 263 333 415
Book Value per Share		 $0.20 $0.15 $4.20 $3.83 $3.14 $2.83 $3.23
Tangible Book Value per Share		 $0.20 $0.15 $3.65 $2.63 $2.32 $2.14 $1.66
Total Capital		 252 231 291 274 234 222 279
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -278 -278 -283 -195 -167 -128 -61
Capital Expenditures (CapEx)		 0.60 0.38 0.80 0.73 1.97 31 9.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.25 -0.34 -0.44 -3.64 3.49 9.61 45
Debt-free Net Working Capital (DFNWC)		 1.06 0.51 282 192 171 138 106
Net Working Capital (NWC)		 1.06 0.51 282 192 171 138 106
Net Nonoperating Expense (NNE)		 2.76 2.91 23 -10 8.39 3.56 -57
Net Nonoperating Obligations (NNO)		 -278 -278 -283 -195 -167 -128 -61
Total Depreciation and Amortization (D&A)		 0.47 0.53 0.60 4.63 0.59 1.97 5.97
Debt-free, Cash-free Net Working Capital to Revenue		 -0.79% -1.45% -0.86% -2.49% 1.55% 3.87% 22.78%
Debt-free Net Working Capital to Revenue		 3.40% 2.16% 558.45% 131.07% 75.84% 55.50% 53.97%
Net Working Capital to Revenue		 3.40% 2.16% 558.45% 131.07% 75.84% 55.50% 53.97%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.38) ($0.76) ($0.35) $0.50
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 42.88M 71.24M 73.52M 77.50M 82.09M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.38) ($0.76) ($0.35) $0.50
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 42.88M 71.24M 73.52M 77.50M 82.09M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 42.88M 72.04M 75.43M 79.69M 86.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.08 -7.25 -17 -37 -48 -24 -16
Normalized NOPAT Margin		 -25.90% -30.94% -33.38% -25.64% -21.18% -9.55% -7.94%
Pre Tax Income Margin		 -34.74% -43.36% -86.48% -19.18% -25.55% -11.08% -10.18%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.89% 0.00%

Quarterly Metrics And Ratios for Strata Critical Medical

This table displays calculated financial ratios and metrics derived from Strata Critical Medical's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 75,433,154.00 77,346,018.00 77,934,085.00 - 79,694,028.00 81,017,314.00 81,695,605.00 86,366,526.00 86,989,143.00 86,526,570.00 88,466,806.00
DEI Adjusted Shares Outstanding		 75,433,154.00 77,346,018.00 77,934,085.00 - 79,694,028.00 81,017,314.00 81,695,605.00 86,366,526.00 86,989,143.00 86,526,570.00 88,466,806.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.06 -0.15 -0.03 - -0.04 -0.05 0.70 -0.10 0.02 -0.12 -0.09
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 13.79% 11.41% -49.52% 14.49% -30.22% 4.20% 36.70% 361.21% 87.45% 60.74% 50.27%
EBITDA Growth		 47.67% 15.04% -339.48% 70.99% 68.79% 68.46% 40.75% -131.23% 341.14% 29.67% 118.79%
EBIT Growth		 47.88% 10.97% -327.47% 69.23% 54.10% 62.66% 24.38% -210.01% 165.77% -137.66% -15.94%
NOPAT Growth		 23.07% 0.49% 3.59% 76.50% 42.39% 59.22% 20.73% -144.87% 25.27% -16.53% 31.86%
Net Income Growth		 58.46% 7.41% -776.12% 71.15% 17.50% 66.95% 3,038.38% 9.80% 161.67% -180.95% -113.26%
EPS Growth		 57.14% 11.76% 0.00% 75.56% 33.33% 66.67% 2,433.33% 0.00% 175.00% -140.00% -112.86%
Operating Cash Flow Growth		 7.74% 202.83% 214.14% 81.20% 98.42% -136.35% -686.89% -374.14% 1,679.27% 285.61% 125.36%
Free Cash Flow Firm Growth		 99.49% 91.67% 7.48% -156.33% -3,936.96% -399.91% -787.92% -1,405.80% -606.43% -484.78% 73.62%
Invested Capital Growth		 -7.10% -3.68% 9.09% 39.57% 17.23% 26.63% 115.92% 254.53% 129.27% 137.06% 13.37%
Revenue Q/Q Growth		 8.50% 31.90% -46.92% -27.40% 513.01% 30.37% -30.37% -53.88% 196.38% 7.60% 2.17%
EBITDA Q/Q Growth		 83.18% -96.26% 43.70% -220.36% -147.46% -0.75% -5.74% 68.63% 466.49% -153.20% 130.72%
EBIT Q/Q Growth		 82.88% -104.41% 43.42% -199.48% -184.57% -0.95% -14.60% 31.74% 150.56% -662.31% 40.26%
NOPAT Q/Q Growth		 72.31% -23.12% 41.62% -136.70% -160.83% 34.67% -13.48% 25.40% -1.30% -27.29% 29.16%
Net Income Q/Q Growth		 87.53% -167.50% 82.75% -401.18% 64.33% -7.16% 1,633.96% -115.38% 124.39% -588.21% 27.59%
EPS Q/Q Growth		 86.67% -150.00% 80.00% -266.67% 63.64% -25.00% 1,500.00% -115.71% 127.27% -500.00% 25.00%
Operating Cash Flow Q/Q Growth		 -66.86% 154.20% -24.61% -127.57% 85.96% -1,145.53% -1,117.27% 77.73% 146.77% 46.38% 66.31%
Free Cash Flow Firm Q/Q Growth		 96.37% -1,043.11% -147.00% -209.56% -251.91% -32.08% -338.71% -38.42% 17.82% -16.20% 80.04%
Invested Capital Q/Q Growth		 25.84% 1.24% 12.19% -2.35% 61.10% 9.35% 91.29% 5.20% 4.18% 13.07% -8.52%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 19.68% 24.07% 20.82% 23.16% 19.62% 25.05% 23.56% -0.89% 20.95% 20.98% 22.70%
EBITDA Margin		 -12.19% -18.13% -19.23% -19.92% -5.45% -5.49% -8.34% -5.67% 7.01% -3.47% 1.04%
Operating Margin		 -19.16% -17.88% -19.67% -15.40% -15.81% -7.00% -11.40% -18.45% -4.41% -7.46% -5.17%
EBIT Margin		 -12.40% -19.22% -20.50% -21.13% -8.16% -6.89% -11.34% -16.78% 2.86% -14.96% -8.75%
Profit (Net Income) Margin		 -8.22% -16.67% -5.42% -18.02% -9.72% -5.29% 116.47% -38.85% 3.20% -14.50% -10.28%
Tax Burden Percent		 98.05% 100.46% 34.73% 98.94% 216.69% 100.56% -594.55% 278.03% 89.68% 100.00% 100.00%
Interest Burden Percent		 67.57% 86.31% 76.13% 86.16% 54.96% 76.32% 172.79% 83.28% 124.52% 96.95% 117.52%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -35.44% -34.29% -30.44% -33.40% -15.86% -12.88% -14.12% -18.25% -6.20% -7.33% -4.61%
ROIC Less NNEP Spread (ROIC-NNEP)		 -37.05% -32.51% -32.37% -30.74% -16.22% -12.66% -71.48% -12.94% -11.90% 2.42% 3.75%
Return on Net Nonoperating Assets (RNNOA)		 24.25% 20.97% 20.40% 19.92% 9.71% 7.25% 29.60% 5.74% 4.24% -0.66% -0.79%
Return on Equity (ROE)		 -11.19% -13.33% -10.05% -13.48% -6.15% -5.63% 15.49% -12.52% -1.96% -8.00% -5.40%
Cash Return on Invested Capital (CROIC)		 -44.73% -48.62% -58.07% -62.62% -29.88% -41.19% -84.02% -123.22% -86.97% -89.17% -18.44%
Operating Return on Assets (OROA)		 -9.49% -15.26% -13.86% -19.06% -4.02% -6.51% -9.82% -11.36% 2.26% -12.97% -7.40%
Return on Assets (ROA)		 -6.29% -13.23% -3.66% -16.25% -4.78% -5.00% 100.85% -26.31% 2.53% -12.57% -8.69%
Return on Common Equity (ROCE)		 -11.19% -13.33% -10.05% -13.48% -6.15% -5.63% 15.49% -12.52% -1.96% -8.00% -5.40%
Return on Equity Simple (ROE_SIMPLE)		 -21.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.91 -8.50 -4.96 -5.86 -3.98 -3.47 -3.94 -2.94 -2.97 -3.79 -2.68
NOPAT Margin		 -13.41% -12.52% -13.77% -10.78% -11.07% -4.90% -7.98% -12.91% -4.41% -5.22% -3.62%
Net Nonoperating Expense Percent (NNEP)		 1.61% -1.79% 1.92% -2.66% 0.36% -0.21% 57.37% -5.31% 5.70% -9.75% -8.36%
Return On Investment Capital (ROIC_SIMPLE)		 -2.92% -3.71% -2.13% -2.64% -1.81% -1.55% -1.39% -1.05% -1.04% -1.36% -0.97%
Cost of Revenue to Revenue		 80.32% 75.93% 79.18% 76.84% 80.38% 74.95% 76.44% 100.89% 79.05% 79.02% 77.30%
SG&A Expenses to Revenue		 33.41% 36.99% 38.46% 34.87% 34.30% 28.45% 33.07% 31.31% 23.16% 19.30% 20.44%
R&D to Revenue		 1.30% 1.43% 1.16% 1.37% 0.00% 1.29% 0.92% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 38.84% 41.95% 40.49% 38.56% 35.43% 32.05% 34.96% 17.55% 25.36% 28.44% 27.88%
Earnings before Interest and Taxes (EBIT)		 -6.39 -13 -7.39 -11 -2.93 -4.88 -5.59 -3.82 1.93 -11 -6.48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.28 -12 -6.94 -11 -1.96 -3.89 -4.11 -1.29 4.72 -2.51 0.77
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.91 1.17 0.98 1.50 0.99 1.46 1.46 1.49 1.27 1.63 1.64
Price to Tangible Book Value (P/TBV)		 1.21 1.53 1.30 1.99 1.33 1.98 2.78 2.90 2.41 4.06 3.91
Price to Revenue (P/Rev)		 0.93 1.13 1.13 1.34 1.66 1.28 1.54 2.11 1.59 1.78 1.61
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 10.24 10.05 7.74 11.34 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.77% 9.95% 12.92% 8.82% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.74 1.47 0.95 2.19 0.98 1.96 1.63 1.63 1.34 1.69 1.75
Enterprise Value to Revenue (EV/Rev)		 0.27 0.53 0.45 0.82 0.74 0.83 1.26 1.80 1.33 1.69 1.46
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 7.56 163.59 0.00 0.00 0.00 0.00 38.25
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.65 -0.65 -0.63 -0.65 -0.60 -0.57 -0.41 -0.44 -0.36 -0.27 -0.21
Leverage Ratio		 1.19 1.23 1.21 1.21 1.17 1.19 1.20 1.16 1.14 1.18 1.19
Compound Leverage Factor		 0.81 1.06 0.92 1.04 0.64 0.91 2.07 0.97 1.42 1.14 1.39
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.45 3.65 3.15 6.20 4.28 6.10 5.27 5.71 5.69 5.41 5.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.35 6.04 6.32 7.07 6.96 5.95 4.39 6.38 5.93 2.64 2.77
Quick Ratio		 7.51 5.60 5.92 6.54 6.50 5.38 4.07 5.11 4.70 1.45 1.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.46 -5.24 -13 -32 -19 -26 -115 -159 -131 -152 -30
Operating Cash Flow to CapEx		 -1,905.76% 52.15% 68.28% -38.29% -9.41% -124.10% -1,437.26% -449.51% 75.01% 228.39% 2,364.50%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.76 0.79 0.68 0.90 0.49 0.95 0.87 0.68 0.79 0.87 0.85
Accounts Receivable Turnover		 11.57 9.49 8.92 11.68 5.75 9.10 8.63 6.60 7.41 7.15 6.99
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 78.28 19.07 11.99 14.71 7.28 9.12 7.74 6.07 6.29 6.88 7.18
Accounts Payable Turnover		 16.77 11.80 9.20 10.36 9.82 12.58 9.31 11.00 11.84 12.58 10.59
Days Sales Outstanding (DSO)		 31.55 38.47 40.92 31.26 63.51 40.11 42.30 55.34 49.29 51.03 52.20
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 21.77 30.94 39.69 35.22 37.18 29.01 39.20 33.18 30.82 29.03 34.46
Cash Conversion Cycle (CCC)		 9.78 7.53 1.23 -3.96 26.33 11.09 3.10 22.16 18.47 22.01 17.74
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 84 85 96 94 99 108 207 218 227 256 234
Invested Capital Turnover		 2.64 2.74 2.21 3.10 1.43 2.63 1.77 1.41 1.40 1.40 1.27
Increase / (Decrease) in Invested Capital		 -6.45 -3.26 7.98 27 15 23 111 156 128 148 28
Enterprise Value (EV)		 63 125 91 204 97 212 337 354 305 433 410
Market Capitalization		 215 269 229 333 218 326 413 415 364 456 452
Book Value per Share		 $3.14 $2.97 $3.00 $2.83 $2.76 $2.75 $3.46 $3.23 $3.28 $3.23 $3.12
Tangible Book Value per Share		 $2.35 $2.28 $2.27 $2.14 $2.06 $2.04 $1.82 $1.66 $1.73 $1.30 $1.31
Total Capital		 237 229 233 222 220 223 283 279 286 279 276
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -152 -144 -138 -128 -121 -115 -76 -61 -59 -23 -42
Capital Expenditures (CapEx)		 0.82 16 9.31 4.58 2.61 2.47 2.60 1.85 5.18 2.49 0.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 18 8.62 6.86 9.61 9.57 15 18 45 44 52 38
Debt-free Net Working Capital (DFNWC)		 171 153 145 138 130 130 95 106 103 75 80
Net Working Capital (NWC)		 171 153 145 138 130 130 95 106 103 75 80
Net Nonoperating Expense (NNE)		 -2.67 2.82 -3.01 3.93 -0.49 0.28 -61 5.90 -5.13 6.73 4.93
Net Nonoperating Obligations (NNO)		 -152 -144 -138 -128 -121 -115 -76 -61 -59 -23 -42
Total Depreciation and Amortization (D&A)		 0.11 0.74 0.46 0.66 0.97 0.99 1.48 2.53 2.80 8.33 7.25
Debt-free, Cash-free Net Working Capital to Revenue		 7.99% 3.61% 3.38% 3.87% 7.29% 5.97% 6.89% 22.78% 19.32% 20.40% 13.58%
Debt-free Net Working Capital to Revenue		 73.79% 64.03% 71.22% 55.50% 99.38% 51.18% 35.36% 53.97% 45.15% 29.39% 28.50%
Net Working Capital to Revenue		 73.79% 64.03% 71.22% 55.50% 99.38% 51.18% 35.36% 53.97% 45.15% 29.39% 28.50%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.06) ($0.15) ($0.03) ($0.11) ($0.04) ($0.05) $0.70 ($0.11) $0.03 ($0.12) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 75.80M 77.60M 78.04M 77.50M 79.89M 81.30M 82.45M 82.09M 85.32M 86.21M 88.27M
Adjusted Diluted Earnings per Share		 ($0.06) ($0.15) ($0.03) ($0.11) ($0.04) ($0.05) $0.70 ($0.11) $0.03 ($0.12) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 75.80M 77.60M 78.04M 77.50M 79.89M 81.30M 82.45M 82.09M 90.17M 86.21M 88.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 77.35M 77.93M 78.31M 79.69M 81.02M 81.70M 86.37M 86.99M 86.53M 88.47M 89.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.91 -8.50 -4.96 -5.86 -3.98 -3.47 -3.94 -2.94 -2.08 -3.79 -2.68
Normalized NOPAT Margin		 -13.41% -12.52% -13.77% -10.78% -11.07% -4.90% -7.98% -12.91% -3.09% -5.22% -3.62%
Pre Tax Income Margin		 -8.38% -16.59% -15.60% -18.21% -4.48% -5.26% -19.59% -13.97% 3.56% -14.50% -10.28%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.50% -0.47% -0.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Data note: The supplied statements identify the company as Blade Air Mobility, Inc. (NASDAQ:BLDE), rather than Strata Critical Medical (NASDAQ:SRTA). The analysis below is based on the financial data provided.

Blade’s latest quarter showed strong revenue growth, but profitability remained uneven. Q2 2026 revenue increased to $72.5 million, up 60.7% from $45.1 million in Q2 2025 and 7.6% from Q1 2026. Gross profit rose to $15.2 million, while the gross margin improved modestly to approximately 21.0% from 20.0% a year earlier.

  • Revenue growth accelerated: Q2 2026 revenue of $72.5 million was the highest among the comparable quarterly figures provided and increased substantially from Q2 2025.
  • Operating cash flow turned positive: Cash generated from operations was $5.7 million in Q2 2026, improving from $3.9 million in Q1 2026 and a $3.1 million use of cash in Q2 2025.
  • Gross profitability improved: Gross profit increased 60.7% year over year to $15.2 million, and the gross margin expanded slightly despite higher revenue-related costs.
  • Balance-sheet liquidity remains adequate in the near term: The company reported $121.0 million of current assets versus $45.8 million of current liabilities, implying a current ratio of approximately 2.6.
  • Debt levels appear limited: Total liabilities were $53.4 million, and the latest cash-flow statement showed only $9,000 of debt repayment during the quarter.
  • Acquisition spending may support future growth: The company spent $35.1 million on acquisitions in Q2 2026, which could expand its operating platform, although the financial return from those investments is not yet clear.
  • Investment balances increased: Short-term investments rose from $66,000 at the end of Q1 2026 to $6.4 million at the end of Q2, but this increase occurred alongside a sharp reduction in cash and may reflect the company’s broader treasury and acquisition activity.
  • Net losses widened sharply: Q2 2026 net loss was $10.5 million, or $0.12 per share, compared with net income of $2.2 million in Q1 2026 and a $3.7 million loss in Q2 2025.
  • Operating losses persist: Operating loss increased to $5.4 million from $3.0 million in Q1 2026, as total operating expenses exceeded gross profit. Amortization expense rose to $6.6 million in Q2 from $1.5 million in Q1.
  • Cash declined materially: Cash and equivalents fell from $58.7 million at the end of Q1 2026 to $16.3 million at the end of Q2. Including short-term investments, the company’s readily available funds declined from approximately $58.8 million to $22.8 million.

The cash-flow profile has improved from the severe operating cash outflows recorded in parts of 2024 and 2025, but it remains dependent on investing activity. In Q2 2026, $5.7 million of operating cash flow was more than offset by $43.9 million of investing outflows, primarily the acquisition and capital spending. As a result, cash and equivalents declined by $42.4 million during the quarter.

The balance sheet is less liquid than it was one year earlier. Cash, restricted cash and short-term investments totaled approximately $23.0 million at June 30, 2026, compared with about $114.0 million at June 30, 2025. At the same time, goodwill and intangible assets totaled approximately $167.0 million, or about half of total assets. That concentration increases the importance of successful acquisitions and creates potential impairment risk if acquired businesses underperform.

Shareholder dilution is another consideration. Weighted-average basic shares increased from approximately 81.3 million in Q2 2025 to 86.2 million in Q2 2026, a rise of roughly 6%. Retained earnings remained negative at $153.9 million, reflecting the company’s cumulative history of losses. Overall, the statements show encouraging revenue expansion and improving operating cash generation, but investors should monitor whether the growth can translate into sustainable operating profits without continued cash depletion or additional equity issuance.

11/13/26 12:35 PM ETAI Generated. May Contain Errors.

Strata Critical Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Strata Critical Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Strata Critical Medical's net income appears to be on an upward trend, with a most recent value of $41.35 million in 2025, compared with -$10.84 million in 2019. The previous period was -$27.31 million in 2024. See Strata Critical Medical's forecast for analyst expectations on what's next for the company.

Strata Critical Medical's total operating income in 2025 was -$22.35 million, based on the following breakdown:
  • Total Gross Profit: $41.13 million
  • Total Operating Expenses: $63.48 million

Over the last 6 years, Strata Critical Medical's total revenue changed from $31.20 million in 2019 to $197.14 million in 2025, a change of 531.9%.

In the past 12 quarters, Strata Critical Medical's cash and equivalents has ranged from $16.32 million in Q2 2026 to $58.75 million in Q2 2025, and is currently $35.14 million as of their latest financial filing in Q3 2026.

Strata Critical Medical had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2019.

Over the last 6 years, Strata Critical Medical's book value per share changed from 0.20 in 2019 to 3.23 in 2025, a change of 1,524.6%.


Related Companies

Financial statements for NASDAQ:SRTA last updated on 11/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
A little-known law has been quietly applied to your savings for years.
Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...
Monetary Gold | Sponsoredtc pixel